Boston Scientific ‘Unlikely to Meet’ Earnings Guidance After Cyberattack. Stock Falls.

Boston Scientific warned Tuesday it is "unlikely to meet" quarterly and full-year earnings guidance following a cyberattack in late August that has disrupted operations. Shares fell on the announcement.

The medical device maker disclosed that the attack's fallout has materially impacted its ability to hit previously issued financial targets for both the third quarter and fiscal 2024. The company had not previously quantified the scope of the breach or its operational toll.

The timing compounds pressure on Boston Scientific, which operates in a capital-intensive sector where supply chain disruptions and manufacturing delays translate directly to revenue shortfalls. The August cyberattack appears to have lingered longer than initially anticipated, forcing management to formally reset investor expectations mid-quarter.

Boston Scientific has not yet provided revised guidance figures or detailed which business units or geographies bore the brunt of the disruption. The company also has not disclosed whether the attack affected product shipments, manufacturing systems, or back-office functions.